SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1878-7479
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease ; day:4 ; month:11 ; year:2021 ; pages:1-16
Neurotherapeutics ; (4.11.2021), 1-16
- Urheber
-
Trujillo-Estrada, Laura
Vanderklish, Peter W.
Nguyen, Marie Minh Thu
Kuang, Run Rong
Nguyen, Caroline
Huynh, Eric
Cunha, Celia da
Javonillo, Dominic Ibarra
Forner, Stefania
Martini, Alessandra C.
Sarraf, Stella T.
Simmon, Vincent F.
Baglietto-Vargas, David
LaFerla, Frank M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13311-021-01143-1
- URN
-
urn:nbn:de:101:1-2022011819430063682727
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Trujillo-Estrada, Laura
- Vanderklish, Peter W.
- Nguyen, Marie Minh Thu
- Kuang, Run Rong
- Nguyen, Caroline
- Huynh, Eric
- Cunha, Celia da
- Javonillo, Dominic Ibarra
- Forner, Stefania
- Martini, Alessandra C.
- Sarraf, Stella T.
- Simmon, Vincent F.
- Baglietto-Vargas, David
- LaFerla, Frank M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer’s disease
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology
Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model
Modeling Alzheimer’s disease in transgenic rats
Reduced slow-wave activity and autonomic dysfunction during sleep precede cognitive deficits in Alzheimer’s disease transgenic mice
Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease
Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model
Predicting probable Alzheimer’s disease using linguistic deficits and biomarkers
Modulation of inflammation in transgenic models of Alzheimer’s disease
A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease
Unmasking selective path integration deficits in Alzheimer’s disease risk carriers
NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer’s disease
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology
Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model
Modeling Alzheimer’s disease in transgenic rats
Reduced slow-wave activity and autonomic dysfunction during sleep precede cognitive deficits in Alzheimer’s disease transgenic mice
Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease
Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model
Predicting probable Alzheimer’s disease using linguistic deficits and biomarkers
Modulation of inflammation in transgenic models of Alzheimer’s disease
A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease
Unmasking selective path integration deficits in Alzheimer’s disease risk carriers
NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer’s disease
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology
Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model
Modeling Alzheimer’s disease in transgenic rats
Reduced slow-wave activity and autonomic dysfunction during sleep precede cognitive deficits in Alzheimer’s disease transgenic mice
Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease
Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model
Predicting probable Alzheimer’s disease using linguistic deficits and biomarkers
Modulation of inflammation in transgenic models of Alzheimer’s disease
A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease